Work

Osimertinib-induced cardiopulmonary toxicity: a network toxicology, molecular docking, and molecular dynamics simulation study

Year: 2026
Type: preprint
Abstract: Context: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is first-line therapy for EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). However, its clinical utility is severely limited by significant cardiotoxicity and pulmotoxicity, which compromise treatment adherence and patient survival. The shared molecular pathogenesis underlying these concurrent adverse effects remains unclear and warrants systematic investigation. Methods We employed an integrated computational framework combining network toxicology, molecular docking, and molecular dynamics (MD) simulations. Multi-database screening identified 119 shared targets between osimertinib and cardiopulmonary toxicity, from which seven hub targets—TP53, ESR1, HDAC1, CREBBP, EP300, HDAC2, and SMARCA4—were prioritized. Enrichment analysis implicated these targets in epigenetic regulation and cancer-related pathways such as microRNAs in cancer. Molecular docking confirmed high-affinity binding of osimertinib to all hub targets (binding free energies − 6.4 to -7.2 kcal/mol). MD simulations demonstrated stable binding with HDAC1 and CREBBP (-20.85 and − 22.92 kcal/mol, respectively) and identified key interacting residues. This work outlines a multi-target, multi-pathway regulatory network and proposes an epigenetics-centered hypothesis: osimertinib-induced cardiopulmonary toxicity may arise from disruption of the CREBBP/EP300-HDAC1/HDAC2 epigenetic balance together with TP53-, ESR1-, and SMARCA4-mediated interactions, providing a theoretical basis for future experimental validation and therapeutic modulation.
Language: English
Subfield: Drug Discovery
Open Access status: green
OpenAlex ID: W7225985635
Cites: 63
Cited by:
Related to: 10